Swiss Chronic Obstructive Pulmonary Disease (COPD) Management Cohort

NCT02065921 | Unknown

• 1 other identifier: EKBB170/06
• Study Type: observational
• Target: 265
• Locations: 1 country
• Sites: 1

Brief Summary

• Tiffenau (FEV17FVC) \< 70 without reversibility (Increase in FEV1 after inhalation of a bronchodilator \<200 ml and \<12%).
• Age: \> 40 years
• Both genders
• Smokers or ex-smokers of at least 20 pack years.
• Informed consent. 3.4 Archiving and Data Retention All study-related records such as medical records, informed consent documents, information regarding participants who discontinued, and other pertinent data will be maintained and therefore retained as long as required by the applicable Swiss regulatory requirements (10 Years). 3.5 Data security The complete data of the study will be entered anonymously into a database. The data is password-protected and can only be accessed by investigators and study members.
• Publication and authorship 4.1 Publication policy
• Substantial contribution to conception and design, acquisition of data, or analysis and interpretation of data.
• Drafting the article or revising it critically for important intellectual content.
• Final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Conditions

Chronic Obstructive Pulmonary Disease; COPD Exacerbation

Keywords

COPD cohort; COPD management; exacerbation

Outcome Measures

Primary Outcomes (1)

• Number of exacerbation

  no. of exacerbation and time to exacerbation over a time period of 2 years.

  24 months

Secondary Outcomes (1)

• Disease progression

  2 years

Study Arms (1)

COPD patients

establishing COPD cohort database to allow high quality research on diagnosis, treatment, complication and progression of COPD on long-term course.

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with newly diagnosed or existing COPD, who are managed in primary-care practices.

You may qualify if:

• Tiffenau (FEV17FVC) \< 70 without reversibility (Increase in FEV1 after inhalation of a bronchodilator \<200 ml and \<12%).
• Age: \> 40 years
• Both genders
• Smokers or ex-smokers of at least 20 pack years.
• Informed consent.

You may not qualify if:

• \< 40 Years
• Tiffenau (FEV17FVC) \> 70

Sponsors & Collaborators

• Prof. Dr. Jörg Leuppi: lead

Study Sites (1)

Cantonal Hospital Baselland, Internal medicine University clinic

Liestal, Basel-Landschaft, 4410, Switzerland

RECRUITING

Related Publications (3)

• Jochmann A, Scherr A, Jochmann DC, Miedinger D, Torok SS, Chhajed PN, Tamm M, Leuppi JD. Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort. Swiss Med Wkly. 2012 Apr 5;142:w13567. doi: 10.4414/smw.2012.13567. eCollection 2012.

  PMID: 22481636 RESULT

• Jochmann A, Neubauer F, Miedinger D, Schafroth S, Tamm M, Leuppi JD. General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med Wkly. 2010 Aug 9;140:10.4414/smw.2010.13053. doi: 10.4414/smw.2010.13053. eCollection 2010.

  PMID: 20407960 RESULT

• Urwyler P, Abu Hussein N, Bridevaux PO, Chhajed PN, Geiser T, Grendelmeier P, Joos Zellweger L, Kohler M, Maier S, Miedinger D, Tamm M, Thurnheer R, Dieterle T, Leuppi JD. Predictive factors for exacerbation and re-exacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohort. Multidiscip Respir Med. 2019 Feb 5;14:7. doi: 10.1186/s40248-019-0168-5. eCollection 2019.

  PMID: 30774953 DERIVED

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Jörg D Leuppi, MD, PhD,Prof.

CONTACT

061 925 2180; joerg.leuppi@ksbl.ch

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Chief of University medical Department Cantonal Hospital Baselland

Study Record Dates

• First Submitted: February 14, 2014
• First Posted: February 19, 2014
• Study Start: September 1, 2006
• Primary Completion: September 1, 2025
• Study Completion: September 1, 2025
• Last Updated: September 6, 2023

Record last verified: 2023-09

Locations

CH (1)